905587-08-8

Basic information

• Product Name: 2,3,6-Trifluoro-5-nitropyridine
• Synonyms: 2,3,6-Trifluoro-5-nitropyridine
• CAS NO: 905587-08-8
• Molecular Formula: C₅HF₃N₂O₂
• Molecular Weight: 178.0688496
• Mol File: 905587-08-8.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2,3,6-Trifluoro-5-nitropyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3,6-Trifluoro-5-nitropyridine(905587-08-8)
• EPA Substance Registry System: 2,3,6-Trifluoro-5-nitropyridine(905587-08-8)

Safety Data

• Hazardous Substances Data: 905587-08-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,3,6-Trifluoro-5-nitropyridine is utilized as an intermediate in the synthesis of various drugs and agrochemicals. Its electron-withdrawing properties contribute to the development of new pharmaceutical compounds with potential therapeutic applications.
Used in Organic Compounds and Materials Development:
This chemical compound is also employed in the creation of organic compounds and materials, where its unique properties can enhance the performance or characteristics of the final products.
Overall, 2,3,6-Trifluoro-5-nitropyridine plays a crucial role in the production of pharmaceuticals and other important compounds, making it an essential component in the advancement of various industries.

Upstream product

• 3512-18-3 2,3,6-trifluoropyridine 

Downstream Products

• 1404085-83-1 N-(3,5-difluorophenyl)-5-fluoro-6-methoxy-3-nitropyridin-2-amine 
• 1404085-71-7 5-fluoro-6-methoxy-3-nitro-N-phenylpyridin-2-amine 
• 907218-76-2 (R)-2-(5,6-difluoro-3-nitropyridin-2-ylamino)-2-(4-fluorophenyl)ethanol 

Relevant articles and documents

Discovery of disubstituted imidazo[4,5- b ]pyridines and purines as potent TrkA inhibitors

Trk receptor tyrosine kinases have been implicated in cancer and pain. A crystal structure of TrkA with AZ-23 (1a) was obtained, and scaffold hopping resulted in two 5/6-bicyclic series comprising either imidazo[4,5-b]pyridines or purines. Further optimization of these two fusion series led to compounds with subnanomolar potencies against TrkA kinase in cellular assays. Antitumor effects in a TrkA-driven mouse allograft model were demonstrated with compounds 2d and 3a.

PYRIDINYL AND PYRAZINYL-(AZA)INDOLSULFONAMIDES

The present invention relates to pyridinyl and pyrazinyl-(aza)indolsulfonamides having GPR17 modulator activity. The compounds have utility in the treatment of a variety of GPR17-associated disorders.

IMIDAZOPYRIDINE DERIVATIVES AS PI3K INHIBITORS

New imidazopyridine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks).

5-AMINOPYRAZOL-3-YL-3H-IMIDAZO [4,5-B] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER

The present invention relates to compounds of Formula (I) and to their pharmaceutical compositions, and to their methods of use. These novel compounds provide a treatment for myeloproliferative disorders and cancer.

9- (PYRAZOL- 3 -YL) - 9H- PURINE-2 -AMINE AND 3- (PYRAZ0L-3-YL) -3H-IMIDAZ0 [4, 5-B] PYRIDIN-5-AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER

The present invention relates to compounds of Formula (I): and to their pharmaceutical compositions, and to their methods of use. These compounds provide a treatment for myeloproliferative disorders and cancer.

CHEMICAL COMPOUNDS

This invention relates to novel compounds having the formula (I): and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.

PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS

This invention relates to novel compounds having the Formula (I) to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.